Explore the latest news from Khondrion and its team.
Khondrion, a Phase 3 clinical-stage biopharmaceutical company advancing therapies for primary mitochondrial diseases, today announced the appointment of Jasper Levink as its new Chief Executive Officer. He succeeds Prof. Jan Smeitink, the founder and CEO of Khondrion and a lifelong advocate formitochondrial medicine.
Khondrion B.V. and Medvisis Switzerland AG today announced an exclusive licensing agreement for the registration and commercialization of sonlicromanol in Switzerland and Liechtenstein for the treatment of Primary Mitochondrial Diseases (PMD). Under the agreement, Medvisis receives exclusive rights to commercialize sonlicromanol in its territory. Financial terms were not disclosed.
NIJMEGEN, the Netherlands – August 4, 2025 – Khondrion announced that the European Commission has granted Orphan Drug Designation (ODD) to its lead investigational therapy, sonlicromanol, for the treatment of all inherited mitochondrial oxidative phosphorylation (OXPHOS) defects.
Khondrion, a clinical-stage biopharmaceutical companypioneering therapies for primary mitochondrial disease (PMD), today announced it has beenawarded an Innovation Credit of up to €5 million from the Netherlands Enterprise Agency, agovernment agency that supports entrepreneurs...
The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion...
52-week Phase 3 trial to investigate potential of novel, brain-penetrant redox-modulator with anti-inflammatory properties, in adult patients with...
Read the interview on pharmaboardroom.com Interview: Jan Smeitink – CEO, Khondrion, The Netherlands Jan Smeitink, CEO of...
Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch...
